<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Gemtuzumab ozogamicin (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e>), a monoclonal antibody used in the treatment of <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) has been linked to the development of <z:e sem="disease" ids="C0948441" disease_type="Disease or Syndrome" abbrv="VOD">venoocclusive disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We conducted a retrospective study of 62 patients with previously treated <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> (<z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>) who underwent allogeneic stem cell (SC) transplantation at our institution from December 2000 to October 2002 to determine whether <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e> exposure prior to allogeneic SC transplantation increases the risk of developing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Fourteen patients received <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e> prior to SC transplantation </plain></SENT>
<SENT sid="3" pm="."><plain>Of 62 patients, 13 (21%) developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e>; 9 (64%) of 14 with prior <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e> exposure developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> compared with 4 (8%) of 48 without prior <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e> exposure (P &lt;.0001) </plain></SENT>
<SENT sid="4" pm="."><plain>Logistic regression controlling for sex, disease status, donor type, and <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> prophylaxis identified prior treatment with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e> as a significant risk factor for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> (odds ratio [OR], 21.6; 95% confidence interval [CI], 4.2-112.2] </plain></SENT>
<SENT sid="5" pm="."><plain>Nine of 10 patients who underwent SC transplantation 3.5 months or less following <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e> developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> compared with none of 4 patients who underwent SC transplantation more than 3.5 months from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e> administration </plain></SENT>
<SENT sid="6" pm="."><plain>Three of 14 patients who received <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e> prior to SC transplantation died of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>We conclude that patients undergoing SC transplantation within a short interval from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e> administration are at increased risk of developing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> </plain></SENT>
</text></document>